公开(公告)号：US20190185882A1

公开(公告)日：2019-06-20

申请号：US16046083

申请日：2018-07-26

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： Stephen R. Quake ,  Jianbin Wang

IPC分类号： C12N15/90 ,  A61K48/00 ,  C12N15/113 ,  C12N15/86 ,  C12N9/16 ,  C12N9/22

CPC分类号： C12N15/907 ,  A61K38/00 ,  A61K48/005 ,  C12N9/16 ,  C12N9/22 ,  C12N15/1133 ,  C12N15/86 ,  C12N2310/20 ,  C12N2330/51 ,  C12N2810/60 ,  C12N2820/60 ,  C12Y301/00 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/393 ,  Y02A50/463 ,  Y02A50/465 ,  Y02A50/467

摘要： The invention provides delivery methods and compositions for antiviral therapeutics. Methods and compositions are provided for targeted delivery of antiviral therapeutics into cells of interest using, for example, viral vectors such as adenovirus, AAV, and replication incompetent HSV. These and other delivery systems can be used as vehicles to deliver DNA vectors encoding a nuclease or a cell-killing gene. These delivery methods can also be used to deliver naked DNA or RNA, protein products, plasmids containing a promoter that is active only in a latent viral state which drives a cell-killing gene, or other therapeutic agents.

公开(公告)号：US20180326004A1

公开(公告)日：2018-11-15

申请号：US16024209

申请日：2018-06-29

申请人： Heat Biologics, Inc.

发明人： Taylor SCHREIBER ,  George FROMM ,  Suresh DE SILVA ,  Neal SCHILLING

IPC分类号： A61K38/17 ,  C07K14/00 ,  C07K19/00 ,  A61K38/00

CPC分类号： A61K38/1774 ,  A61K38/00 ,  A61K38/177 ,  C07K14/00 ,  C07K19/00 ,  C07K2319/00 ,  C07K2319/74 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/393 ,  Y02A50/409 ,  Y02A50/491

摘要： The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.

公开(公告)号：US10081609B2

公开(公告)日：2018-09-25

申请号：US14772284

申请日：2014-03-14

申请人： The Broad Institute, Inc. ,  Massachusetts Institute of Technology

发明人： Sangeeta Bhatia ,  Jing Shan ,  Michelle Palmer ,  Nathan Ross

IPC分类号： C12N5/00 ,  C07D263/24 ,  C12N5/071 ,  A01K67/027 ,  A61K31/137 ,  A61K31/403 ,  A61K31/4035 ,  A61K31/4174 ,  A61K31/4409 ,  A61K35/407 ,  C07C211/32 ,  C07D209/48 ,  C07D209/88 ,  C07D213/75

CPC分类号： C07D263/24 ,  A01K67/0278 ,  A01K2227/105 ,  A01K2267/0331 ,  A61K31/137 ,  A61K31/403 ,  A61K31/4035 ,  A61K31/4174 ,  A61K31/4409 ,  A61K35/407 ,  C07C211/32 ,  C07D209/48 ,  C07D209/88 ,  C07D213/75 ,  C12N5/067 ,  C12N2501/02 ,  C12N2501/115 ,  C12N2501/12 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/237 ,  C12N2501/999 ,  C12N2503/02 ,  C12N2506/45 ,  C12N2533/90 ,  Y02A50/387 ,  Y02A50/463

摘要： The present invention provides methods of inducing proliferation of and/or differentiating cells comprising contacting cells with compounds within the methods of the invention. The present invention further provides cells obtainable by the methods of the invention. Liver disease affects more than 500 million people worldwide. Organ transplantation is the gold standard for treatment of liver failure, but organ shortages are acute.

公开(公告)号：US10066241B2

公开(公告)日：2018-09-04

申请号：US14725943

申请日：2015-05-29

申请人： THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

发明人： Stephen R. Quake ,  Jianbin Wang

IPC分类号： C12N15/86 ,  C12N9/16 ,  A61K38/00 ,  C12N15/90 ,  C12N15/113 ,  C12N9/22

CPC分类号： C12N15/907 ,  A61K38/00 ,  A61K48/005 ,  C12N9/16 ,  C12N9/22 ,  C12N15/1133 ,  C12N15/86 ,  C12N2310/20 ,  C12N2330/51 ,  C12N2810/60 ,  C12N2820/60 ,  C12Y301/00 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/393 ,  Y02A50/463 ,  Y02A50/465 ,  Y02A50/467

摘要： The invention provides delivery methods and compositions for antiviral therapeutics. Methods and compositions are provided for targeted delivery of antiviral therapeutics into cells of interest using, for example, viral vectors such as adenovirus, AAV, and replication incompetent HSV. These and other delivery systems can be used as vehicles to deliver DNA vectors encoding a nuclease or a cell-killing gene. These delivery methods can also be used to deliver naked DNA or RNA, protein products, plasmids containing a promoter that is active only in a latent viral state which drives a cell-killing gene, or other therapeutic agents.

公开(公告)号：US10059733B2

公开(公告)日：2018-08-28

申请号：US15122506

申请日：2015-02-27

申请人： NUCORION PHARMACEUTICALS, INC.

发明人： Zucai Suo ,  David J. Taggart ,  Sheng Cao

IPC分类号： A01N43/04 ,  A61K31/70 ,  C07H19/06 ,  C07H19/10 ,  C07H19/11 ,  A61K45/06 ,  A61K31/7068 ,  A61K31/7064 ,  A61K31/706

CPC分类号： C07H19/06 ,  A61K31/706 ,  A61K31/7064 ,  A61K31/7068 ,  A61K45/06 ,  C07H19/10 ,  C07H19/11 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/463

摘要： Gemcitabine analogs, including monophosphorylated analogs, are described herein and are suitable for use in pharmaceutical compositions, kits and treatment methods. The treatment methods include treatment of viral infections, including, but not limited to, treatment of Hepatitis C Virus, and uncontrolled cellular proliferation, including cancer, such as, but not limited to, non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer, liver cancer, esophageal cancer and lymphoma.

公开(公告)号：US20180228921A1

公开(公告)日：2018-08-16

申请号：US15895414

申请日：2018-02-13

申请人： EXCISION BIOTHERAPEUTICS, INC.

发明人： Kamel Khalili ,  Won-Bin Young

IPC分类号： A61K49/00 ,  A61K38/46 ,  A61K31/7088 ,  A61P31/18

CPC分类号： A61K49/0013 ,  A01K2227/105 ,  A01K2267/0337 ,  A01K2267/0393 ,  A61K31/7088 ,  A61K38/465 ,  A61K48/00 ,  A61K49/0097 ,  A61P31/18 ,  C12N2740/16043 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/391 ,  Y02A50/393 ,  Y02A50/397 ,  Y02A50/463 ,  Y02A50/467

摘要： A reporter gene that can be administered to an individual such as HIV-BAL-eLuc in order to detect the presence of a virus. A method of detecting the presence of virus in an individual, by administering a reporter gene to the individual, associating the reporter gene with the virus, imaging the individual, and detecting the presence of virus in the individual. A method of determining the efficacy of a treatment for a virus, by administering a reporter gene to the individual receiving treatment for the virus, associating the reporter gene with the virus, imaging the individual, detecting the presence of virus in the individual, and determining if the treatment is effective.

公开(公告)号：US09994613B2

公开(公告)日：2018-06-12

申请号：US15288863

申请日：2016-10-07

申请人： VERTEX PHARMACEUTICALS INCORPORATED

发明人： Marion W. Wannamaker ,  Robert J. Davies

IPC分类号： C07K5/062 ,  A61K38/00 ,  A61P17/00 ,  C07K5/06 ,  C07D307/02 ,  C07D477/02 ,  C07D477/20 ,  C07K5/02 ,  C07K5/08 ,  C07D207/16 ,  C07K5/083

CPC分类号： C07K5/06034 ,  A61K38/00 ,  C07D207/16 ,  C07D307/02 ,  C07D477/02 ,  C07D477/20 ,  C07K5/0202 ,  C07K5/0205 ,  C07K5/06 ,  C07K5/06008 ,  C07K5/06191 ,  C07K5/08 ,  C07K5/0808 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/475

摘要： This invention describes an ICE inhibitor prodrug (I) having good bioavailability. Compound I is useful for treating IL-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, Alzheimer's disease, myocardial infarction, congestive heart failure, Huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.

公开(公告)号：US09968628B2

公开(公告)日：2018-05-15

申请号：US13675937

申请日：2012-11-13

申请人： Idenix Pharmaceuticals, Inc. ,  Universita degli studi di Cagliari

发明人： Jean-Pierre Sommadossi ,  Paolo LaColla

IPC分类号： A61K31/7052 ,  A61K31/7072 ,  A61K31/7076 ,  C07H19/06 ,  C07H19/10 ,  C07H19/16 ,  C07H19/20 ,  C07H19/073 ,  C07H19/23 ,  A61K31/7056 ,  A61K31/7064 ,  A61K38/21

CPC分类号： A61K31/7072 ,  A61K31/7052 ,  A61K31/7056 ,  A61K31/7064 ,  A61K31/7076 ,  A61K38/21 ,  C07H19/06 ,  C07H19/073 ,  C07H19/10 ,  C07H19/16 ,  C07H19/20 ,  C07H19/23 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389

摘要： A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

公开(公告)号：US20180085370A1

公开(公告)日：2018-03-29

申请号：US15659526

申请日：2017-07-25

申请人： Gilead Sciences, Inc.

发明人： Manoj C. Desai ,  Randall L. Halcomb ,  Paul Hrvatin ,  Hon Chung Hui ,  Ryan McFadden ,  Paul A. Roethle ,  Hong Yang

IPC分类号： A61K31/519 ,  A61K38/21 ,  C07D475/06 ,  A61K38/16 ,  A61K31/708 ,  A61K31/7072 ,  A61K31/7056 ,  A61K31/683 ,  A61K31/573 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/551 ,  A61K31/527 ,  C07D403/12 ,  C07D475/10 ,  C07D487/04 ,  C07D475/12 ,  C07D475/08

CPC分类号： A61K31/519 ,  A61K31/527 ,  A61K31/5377 ,  A61K31/551 ,  A61K31/573 ,  A61K31/683 ,  A61K31/7056 ,  A61K31/7072 ,  A61K31/708 ,  A61K38/16 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  C07D403/12 ,  C07D475/06 ,  C07D475/08 ,  C07D475/10 ,  C07D475/12 ,  C07D487/04 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/391 ,  Y02A50/393 ,  Y02A50/395

摘要： Provided are modulators of TLRs of Formula II: pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

公开(公告)号：US20180072729A1

公开(公告)日：2018-03-15

申请号：US15817896

申请日：2017-11-20

申请人： ONCOCEUTICS, INC. ,  PROVID PHARMACEUTICALS INC.

发明人： Joshua E. ALLEN ,  Martin STOGNIEW ,  Richard S. POTTORF ,  Bhaskara Rao NALLAGANCHU ,  Gary OLSON ,  Yanjun SUN

IPC分类号： C07D471/14

CPC分类号： C07D471/14 ,  A61K31/337 ,  A61K31/519 ,  A61K45/06 ,  C07D471/12 ,  C07D487/14 ,  Y02A50/387 ,  Y02A50/463 ,  Y02A50/467 ,  A61K2300/00

摘要： This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10): as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.